Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y1ZU
|
|||
| Former ID |
DIB006726
|
|||
| Drug Name |
SA-237
|
|||
| Synonyms |
Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai
Click to Show/Hide
|
|||
| Indication | Encephalopathy [ICD-11: 8E47; ICD-10: G93.4] | Phase 3 | [1] | |
| Neuromyelitis optica [ICD-11: 8A43; ICD-10: G36.0; ICD-9: 341] | Phase 3 | [1], [2] | ||
| Rheumatoid arthritis [ICD-11: FA20] | Phase 3 | [3] | ||
| Company |
Chugai Pharmaceutical Co Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 6 receptor (IL6R) | Target Info | Antagonist | [4] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Reactome | MAPK3 (ERK1) activation | |||
| MAPK1 (ERK2) activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Senescence and Autophagy in Cancer | ||||
| IL-6 signaling pathway | ||||
| Differentiation Pathway | ||||
| Interleukin-6 signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02073279) Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD. U.S. National Institutes of Health. | |||
| REF 4 | IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.